Navigation Links
e-MDs Continues Track Record of Employee and Revenue Growth
Date:3/2/2011

AUSTIN, Texas, March 2, 2011 /PRNewswire/ -- e-MDs, a leading provider of electronic health records (EHRs), is proud to announce another year of record revenue and employee growth.  In 2010 e-MDs doubled their growth rate from the previous two years.  Total employee count grew from 209 to 275 through the course of 2010, a 31% increase, expanding nearly every department with both entry level and senior positions.  The company anticipates significant growth will continue through 2011 in the areas of provider training, implementation, customer support, meaningful use assistance, health information exchanges, special projects (e.g., the Patient Centered Medical Home), practice optimization, patient safety initiatives, research, design, development, quality assurance, content development, and education.  

(Logo: http://photos.prnewswire.com/prnh/20091117/DA12265LOGO)

e-MDs began an escalation in hiring in early 2009, and continued to see significant growth throughout 2010.  In order to maintain the highest level of customer satisfaction during this period of expansion, e-MDs continues to focus on its commitment to hiring and training a staff that will be an asset to customers.  A US-based support team is always available to e-MDs customers and is one of the many reasons why the company continues to garner numerous top rankings in independent surveys, including receiving two 2010 Best in KLAS awards for Ambulatory EHR (2-5 physician) and Practice Management (2-5 physician).

"A large portion of our customer growth can be attributed to e-MDs being selected by the majority of regional extension centers that have created some form of vendor short list," said Patrick Hall, Executive Vice President of Business Development at e-MDs.  "We are one of the top selected vendors which, given the rigorous nature of the selection processes that evaluate custom
'/>"/>

SOURCE e-MDs
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor
2. e-MDs Clients Win HIMSS Davies Awards of Excellence
3. Adult Smoking Rate Continues Downward Trend
4. Gilbert Hospital Continues Cutting Edge Treatments
5. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
6. Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss
7. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
8. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
9. Carpet One Floor & Home Continues Making Dramatic Strides in Funding Breast Cancer Research and Awareness
10. Medarex Announces Ipilimumab Program Continues to Move Forward
11. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... BOULDER, Colo. , Nov. 25, 2014 ... ARRY ) today announced that its Chief ... speak at the following upcoming conferences.  The ... conferences through webcasts on the Array BioPharma ... ConferenceDate:Wednesday, December 3, 2014Time:1:30 p.m.  Eastern Time ...
(Date:11/26/2014)... , Nov. 25, 2014 Amgen (NASDAQ: ... today announced that AMAGINE-2 TM , a pivotal, multi-arm Phase ... 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints ... at week 12. Brodalumab 210 mg given every two weeks ... be superior to Stelara on the primary endpoint of achieving ...
(Date:11/26/2014)... Nov. 25, 2014 Immune Pharmaceuticals Inc. ... stage biopharmaceutical company that engages in the development ... of inflammatory diseases and cancer, today announced the ... of 3,450,000 units, with each unit consisting of ... value $0.0001 per share, and one warrant to ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company ... purification, today reported that the U.S. Food and Drug Administration has issued ... , , ... final decision letter from the FDA for the company,s 510(k) submission which ...
... July 7 ICAP ... division of ICAP plc (IAP.L), is offering for ... drug formulation technology Captisol® owned by CyDex Pharmaceuticals ... fifteen related foreign counterparts covering two important close-to-market, ...
Cached Medicine Technology:Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System 2Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System 3Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System 4ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc. 2ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc. 3
(Date:11/26/2014)... 26, 2014 The family foundation of ... the Mesothelioma Applied Research Foundation (Meso Foundation), half of ... Patient Travel Grant Program . The focus area ... create grant partnerships with organizations that can generate transformational ... Schulze is the founder and chairman emeritus of Best ...
(Date:11/26/2014)... 26, 2014 German scientists say carbon-based ... can cause mesothelioma that looks and acts similar to ... article on the research. Click here to read ... for Toxicology and Experimental Medicine in Hannover injected 500 ... of the rats eventually developed mesothelioma , how ...
(Date:11/26/2014)... 26, 2014 With a redesign of ... Steven Meier has enhanced the user experience and ... prospective patients an online destination for orthopedic and sports ... present the new and improved version of the website. ... easier than ever for current and prospective patients to ...
(Date:11/26/2014)... 2014 ISI Telemanagement Solutions, Inc., ... been award the 2014 Lync Pioneer Award ... comes as a great honor to ISI, who ... ecosystem. Specifically, ISI offers an integrated collaboration reporting ... communication, including voice, video, Lync IM, and conferencing. ...
(Date:11/26/2014)... For those with a New Year’s resolution to get ... at the University of Colorado Anschutz Health and Wellness ... The 45- 60 minute classes have just started and are ... club memberships. , LES MILLS BODYPUMP™ exercise classes strengthen, condition ... at fast results , By focusing on low weight ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2
... ATLANTA, Sept. 8 Craneware, Inc. (AIM: CRW.L), a leader in sustainable financial improvement ... ended June 30, 2009. , , Financial Highlights , ... in the year totaling $43.2m (FY08: $25.7m), 68% up from the previous year, contributing ... to $23.0m (FY08: $18.7m) , 51% ...
... , , WASHINGTON, Sept. 8 More ... in scrubs and lab coats this week to bring an angry message ... The doctors, all traveling as individuals and at their own expense, will ... meet with the doctors of Congress, including Tom Price, M.D. (GA) and ...
... , , , ... and Walmart,s Leslie Dach to discuss areas of bipartisan agreement in ... The Bipartisan Policy Center (BPC) and Better Health Care Together ... agreement among political, business and labor leaders in the health reform ...
... maintained in mice given HDAC inhibitors, study finds , TUESDAY, ... cancer drug might be able to restore day-to-day memory ... common form of dementia among the elderly, is expected to ... sign is loss of short-term memory. , "People often joke ...
... , BRISTOL, Va. and BIRMINGHAM, Ala., ... (NYSE: HLS ) today announced that a joint venture ... of public need (COPN) to open a new inpatient rehabilitation hospital ... Bristol and throughout Southwest Virginia to have access to comprehensive, high-quality ...
... , NEW YORK, Sept. 8 ... its catalogue. , , Lung Cancer ... http://www.reportlinker.com/p0131247/Lung-Cancer-Therapeutics.html , , This report ... Millions of US$. The US market for Non-Small Cell Lung Cancer ...
Cached Medicine News:Health News:Craneware Announces Fiscal Year-End Results 2Health News:Craneware Announces Fiscal Year-End Results 3Health News:Dr. 'Smith' Comes to Washington: Angry Physicians From All 50 States Rally in DC on Sept 10 2Health News:Bipartisan Policy Center and Better Health Care Together to Host Joint Health Care Forum Tomorrow 2Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 2Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 3Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 4Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 5Health News:Reportlinker Adds Lung Cancer Therapeutics Report 2Health News:Reportlinker Adds Lung Cancer Therapeutics Report 3Health News:Reportlinker Adds Lung Cancer Therapeutics Report 4Health News:Reportlinker Adds Lung Cancer Therapeutics Report 5Health News:Reportlinker Adds Lung Cancer Therapeutics Report 6Health News:Reportlinker Adds Lung Cancer Therapeutics Report 7Health News:Reportlinker Adds Lung Cancer Therapeutics Report 8Health News:Reportlinker Adds Lung Cancer Therapeutics Report 9Health News:Reportlinker Adds Lung Cancer Therapeutics Report 10